

topenia analysis by population PKPD modeling and simulations. *Eur J Pharmacol.* 2025;1002:177777.

18. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. *Clin Pharmacokinet.* 2003;42(13):1129-1140.

19. Liu J, Pang Y, Li W, et al. Impact of hepatic impairment and renal failure on the pharmacokinetics of linezolid and its metabolites: contribution of hepatic metabolism and renal excretion. *Antimicrob Agents Chemother.* 2025;69(5):e0189224.

20. Gou J, Li Q, Fan N, et al. High accumulation of linezolid and its major metabolite in the serum of patients with hepatic and renal dysfunction is significantly associated with thrombocytopenia and anemia. *Microbiol Spectr.* 2025;13(7):e0249324.

21. Crass RL, Cojutti PG, Pai MP, et al. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety. *Antimicrob Agents Chemother.* 2019;63(8):e00605-19.

22. Brier ME, Stalker DJ, Aronoff GR, et al. Pharmacokinetics of linezolid in subjects with renal dysfunction. *Antimicrob Agents Chemother.* 2003;47(9):2775-2780.

23. Zhang SH, Zhu ZY, Chen Z, et al. Population Pharmacokinetics and Dosage Optimization of Linezolid in Patients with Liver Dysfunction. *Antimicrob Agents Chemother.* 2020;64(6):e00133-20.

24. SanFilippo S, Turgeon J, Michaud V, et al. The Association of Serotonin Toxicity with Combination Linezolid-Serotonergic Agent Therapy: A Systematic Review and Meta-Analysis. *Pharmacy (Basel).* 2023;11(6):182.

25. Höhl R, Raschofer F, Kinzig M, et al. TDM Study Group. Underexposure of linezolid in critically ill patients with extracorporeal membrane oxygenation (ECMO): results from a monocentric study including blood samples from 52 patients. *Infection.* 2025 Nov 6.

26. Liu T, Yuan Y, Wang Ch, et al. Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study. *J Antimicrob Chemother.* 2024;79(8):1938-1950.

27. Xu Y, Yang X, Liang P, et al. Linezolid dose adjustment according to therapeutic drug monitoring helps reach the goal concentration in severe patients, and the oldest seniors benefit more. *BMC Infect Dis.* 2023;23(1):840.

28. Chen X, Yang L, Zhang Q, et al. Population pharmacokinetic model of linezolid and its metabolite PNU-142300 in elderly patients. *J Antimicrob Chemother.* 2025;80(11):3001-3010.

29. Závřelová A, Merdita S, Žák P, et al. Population Pharmacokinetic Model-Based Optimization of Linezolid Dosing in Hematological Patients With Suspected or Proven Gram-Positive Sepsis. *Clin Transl Sci.* 2025;18(9):e70346.